Highlight
SLA-DR knockout pigs generated on a GGTA1/B4GALNT2-deficient background remained healthy beyond 16 months and tested negative for 55 pathogens with zoonotic potential by digital droplet PCR.
In a rhesus macaque renal xenotransplant model, 2 recipients achieved long-term survival beyond 365 days with preserved graft function, including serum creatinine of 0.8 mg/dL in both long-term survivors.
The 2 early graft losses, at 7 and 126 days, were linked not to apparent failure of the SLA-DR deletion strategy itself, but to pre-existing donor-specific anti-SLA antibodies detected by bead crossmatch.
The study supports SLA-DR deletion as a biologically plausible and operationally feasible strategy to reduce class II porcine immunogenicity, while underscoring that residual non-DR SLA incompatibilities still matter.
Background and Clinical Context
Kidney failure remains a major global health problem, and the shortage of suitable human donor organs continues to limit transplantation as definitive therapy for end-stage kidney disease. Xenotransplantation, particularly from genetically engineered pigs, has emerged as a serious translational strategy to expand organ availability. Over the last decade, the field has progressed from proof-of-concept experiments focused on hyperacute rejection to increasingly sophisticated donor engineering designed to address complement activation, coagulation dysregulation, innate immune injury, and adaptive cellular and humoral responses.
Among these immunologic barriers, porcine major histocompatibility complex antigens remain highly relevant. In pigs, the swine leukocyte antigen (SLA) system is the analogue of the human HLA system. SLA-DR is the dominant class II MHC antigen in pigs and is therefore a logical target if one aims to reduce direct xenogeneic CD4-positive T-cell recognition and potentially limit class II-driven antibody responses. However, removing a major class II antigen raises practical concerns. These include whether such pigs can be generated reliably, whether they remain healthy, and whether deletion changes susceptibility to infection or creates an unacceptable zoonotic biosafety profile.
The present study by Adams and colleagues addresses a clinically important translational question: can donor pigs lacking SLA-DR be produced safely and can their kidneys function long term in a preclinical nonhuman primate model? The work is notable because it evaluates not only graft performance but also donor animal health and extensive pathogen screening, both of which are central to eventual human application.
Study Design
Donor pig engineering
The investigators created SLA-DR knockout pigs using CRISPR/Cas genome editing and somatic cell nuclear transfer. These animals were generated on a double carbohydrate xenoantigen-deficient background, specifically GGTA1/B4GALNT2 deficient pigs. This background is itself important because it removes 2 major glycan targets of human and nonhuman primate natural antibodies: alpha-gal, generated by GGTA1, and the Sda antigen, generated by B4GALNT2.
Safety and infectious assessment
To address zoonotic safety, pigs were tested for 55 pathogens with zoonotic infectious potential using digital droplet PCR assays. The abstract reports that the animals were devoid of these 55 pathogens and remained healthy for more than 16 months, suggesting that SLA-DR deletion did not produce an overtly compromised health phenotype within the observation window.
Preclinical transplantation model
Four kidneys from GGTA1/B4GALNT2/SLA-DR knockout pigs were transplanted into immunosuppressed rhesus monkeys. The abstract does not provide the full immunosuppressive regimen, histopathology details, or comparator arm, so the interpretation must remain tied to a small proof-of-concept series rather than a controlled efficacy study.
Primary outcomes
The clinically meaningful endpoints were recipient survival and renal function after xenotransplantation. Renal function was monitored to determine whether these prototype donor kidneys could provide life-supporting kidney function. The investigators also evaluated causes of graft failure, including the presence of donor-specific anti-SLA antibodies using an SLA bead crossmatch assay.
Key Results
Successful generation of viable, apparently healthy donor pigs
A major contribution of the study is that SLA-DR knockout pigs were successfully produced and remained healthy more than 16 months later. This observation is important because MHC class II deletion could, in principle, disrupt immune competence, infection susceptibility, or developmental fitness. The abstract does not provide detailed veterinary immunophenotyping, fertility data, or longitudinal hematologic and infectious outcomes, but the headline finding is reassuring: the edited pigs were viable and clinically healthy over a prolonged follow-up period.
Favorable zoonotic screening profile
The donor pigs were reported to be devoid of 55 pathogens with zoonotic infectious potential as assessed by digital droplet PCR. In the xenotransplantation field, safety concerns extend beyond conventional transplantation because donor species-specific microorganisms, including latent or endogenous pathogens, may theoretically cross species barriers under intense recipient immunosuppression. Although the abstract does not enumerate each pathogen or discuss porcine endogenous retrovirus in detail, the broad screening platform and negative findings strengthen the translational relevance of the donor platform.
Long-term kidney xenograft function is achievable
The most compelling efficacy signal in the paper is durable renal support in 2 of the 4 rhesus recipients. Reported survival times were 7 days, 126 days, more than 365 days, and more than 365 days. Both long-term survivors maintained serum creatinine at 0.8 mg/dL, indicating preserved graft function and suggesting that the donor kidneys were capable of sustained, life-supporting renal performance in this model.
For a preclinical xenotransplant study, survival beyond 1 year with stable creatinine is a notable benchmark. It suggests that the genetically engineered graft can not only avoid immediate catastrophic rejection but also maintain filtration and homeostatic function over a prolonged period under ongoing immunosuppression.
Early losses were associated with preformed donor-specific anti-SLA antibodies
Equally instructive are the 2 graft failures. The recipients who survived 7 and 126 days were found to have donor-specific pre-transplant SLA antibodies detected by an SLA bead crossmatch assay. This is a crucial mechanistic observation. It argues that the failures were not necessarily evidence that SLA-DR deletion is ineffective, but rather that residual antigenic targets within the donor pig SLA repertoire remained clinically important.
In practical terms, the data suggest that removing SLA-DR may reduce one major immunogenic axis, but it does not render the graft immunologically invisible. If a recipient is already sensitized to other class I or class II SLA antigens still present on the donor organ, substantial humoral risk persists. This point is highly relevant for clinical translation, because it reframes donor engineering as one component of immunologic risk reduction rather than a complete substitute for compatibility testing.
Mechanistic and Translational Interpretation
The study supports a biologically plausible model in which class II antigen reduction can attenuate adaptive immune recognition of porcine grafts. SLA-DR, as a dominant porcine MHC class II molecule, likely contributes to direct T-cell allorecognition and to downstream antibody formation. By deleting SLA-DR, the investigators may have reduced one prominent pathway of recipient immune activation.
At the same time, the observation of antibody-mediated graft vulnerability despite SLA-DR deletion highlights the layered nature of xenogeneic immunity. Carbohydrate antigens, class I and residual class II protein antigens, endothelial activation, innate immune triggers, and coagulation incompatibilities all interact. The best-performing current donor platforms therefore tend to combine multiple edits rather than rely on any single modification. In that framework, the present work is best viewed as incremental but meaningful engineering: an additional refinement that appears feasible, safe in donor animals, and potentially useful when integrated into broader donor-recipient matching strategies.
One particularly important translational implication is the value of crossmatch testing against porcine antigens. In human allotransplantation, donor-specific antibody assessment is standard practice. This study suggests that analogous porcine bead-based crossmatching may become essential in xenotransplant workflows, especially if clinical candidates have heterogeneous exposure histories or variable anti-pig reactivity. The fact that pre-transplant anti-SLA antibodies predicted poor outcomes in this small series provides a practical lesson for trial design and candidate selection.
Strengths of the Study
The study has several notable strengths. First, it addresses a highly specific and clinically relevant engineering question rather than simply reporting another transplantation survival record. Second, it integrates donor animal viability, infectious screening, and recipient graft function, which together are more informative for translation than isolated immunologic assays alone. Third, the authors report a clear explanation for the early failures, supported by bead crossmatch evidence, allowing a more nuanced interpretation than a simple binary success-or-failure narrative.
Another strength is the duration of successful graft function. More than 1 year of survival with normal-range creatinine in 2 recipients is a strong signal that the edited kidneys can sustain meaningful physiologic function. In a field where short-term survival can still be confounded by surgical, hemodynamic, and innate immune complications, durable function carries particular weight.
Limitations and Remaining Questions
The limitations are equally important. The sample size is only 4 transplants, which is appropriate for a proof-of-concept preclinical study but far too small to define reproducibility, estimate effect size, or isolate the specific contribution of SLA-DR deletion from other variables. No parallel comparator group is provided in the abstract, such as GGTA1/B4GALNT2-deficient kidneys without SLA-DR deletion under the same conditions. Without that comparison, one cannot quantify how much of the observed success is attributable specifically to the DR knockout.
The abstract also does not report detailed pathology, the exact immunosuppressive regimen, rejection phenotypes, proteinuria, histologic chronic injury, hematologic consequences, or donor pig immunobiology. These missing details matter. For example, if long-term graft function required intensive immunosuppression not acceptable for human translation, enthusiasm would need to be tempered. Likewise, a more granular understanding of whether graft injury in the failed cases was antibody-mediated rejection, thrombotic microangiopathy, cellular rejection, or mixed injury would sharpen mechanistic conclusions.
Another unresolved issue is whether SLA-DR deletion could have unforeseen infectious or immunologic consequences over longer donor pig lifespans or across breeding lines. The more than 16-month healthy follow-up is reassuring but not definitive. Finally, the rhesus macaque model, while still valuable, does not perfectly recapitulate human anti-pig immunity. Some carbohydrate and protein antigen responses differ between species, and this complicates direct extrapolation.
Clinical Relevance for Human Kidney Xenotransplantation
Despite these limitations, the findings are clinically relevant. The study supports the idea that donor pigs can be engineered beyond glycan deletion alone to address protein antigenicity in a targeted manner. For future pig-to-human kidney transplantation, this could help build donor platforms with lower immunogenic burden and potentially improve the balance between graft control and immunosuppression intensity.
The work also reinforces a practical message for first-in-human or early-phase clinical protocols: donor engineering should be paired with careful recipient immunologic profiling. Even if major xenoantigens and SLA-DR are removed, patients may still harbor antibodies against remaining porcine antigens. A standardized xenocrossmatch strategy may therefore become as indispensable in xenotransplantation as HLA antibody testing is in allotransplantation.
In policy and regulatory terms, the pathogen-screening data are also meaningful. Regulatory acceptance of clinical xenotransplantation depends not only on graft efficacy but also on robust biosurveillance and source-animal biosecurity. Demonstrating that a novel gene-edited donor line can be maintained in a pathogen-screened state helps address one of the field’s most persistent concerns.
Conclusion
This study provides persuasive early evidence that SLA-DR deletion is a viable addition to the genetic engineering toolkit for renal xenotransplantation. The donor pigs were viable, remained healthy for more than 16 months, and screened negative for 55 pathogens with zoonotic potential. In rhesus monkey recipients, these kidneys provided durable, life-supporting function in 2 of 4 cases, with long-term survivors maintaining serum creatinine at 0.8 mg/dL.
The most important interpretive nuance is that the strategy appears promising but not sufficient in isolation. The early graft losses were associated with preformed donor-specific anti-SLA antibodies against antigens other than the deleted DR target, emphasizing that residual porcine antigenicity remains clinically relevant. Taken together, the findings support continued development of SLA-DR knockout donor pigs for pig-to-human renal xenotransplantation, ideally alongside rigorous xenocrossmatching, broader donor engineering, and carefully designed clinical trial safeguards.
Funding and Trial Registration
Funding information was not provided in the abstract supplied here. A ClinicalTrials.gov registration number was not reported in the abstract. Readers should consult the full Annals of Surgery publication for complete funding disclosures, conflicts of interest, and protocol details.
References
1. Adams AB, Tector M, Burlak C, Estrada J, Reyes L, Copsel S, Muniz C, Novara Gennuso V, Martucci M, Iwakoshi N, Dryden M, Faber D, Ray B, Haver H, Hariharan J, Vianna R, Tector AJ. Swine Leukocyte Antigen DR Deletion is a Viable Option for Donor Pigs Used in Renal Xenotransplantation. Annals of Surgery. 2026-06-05. PMID: 42244457.
2. Montgomery RA, Stern JM, Lonze BE, Tatapudi VS, Mangiola M, Wu M, Weldon C, Lawson N, Detville C, Dieter RA, et al. Results of Two Cases of Pig-to-Human Kidney Xenotransplantation. New England Journal of Medicine. 2025;392:1627-1638.
3. Cooper DKC, Ezzelarab MB, Hara H, Iwase H, Lee W, Wijkstrom M, Bottino R. The pathobiology of pig-to-primate xenotransplantation: a historical review. Xenotransplantation. 2016;23(2):83-105.
4. Denner J. Reduction of the risk of transmission of porcine endogenous retroviruses by xenotransplantation. Viruses. 2021;13(10):1929.
5. Fishman JA. Infectious disease risks in xenotransplantation. American Journal of Transplantation. 2018;18(8):1857-1864.
